![NOVASEP named Import/Export National Champion for France in The European Business Awards 2016/17](https://ala.associates/wp-content/uploads/2016/09/Michel-Spagnol_B-1080x675.jpg)
![NOVASEP named Import/Export National Champion for France in The European Business Awards 2016/17](https://ala.associates/wp-content/uploads/2016/09/Michel-Spagnol_B-1080x675.jpg)
![Vygon launches new product](https://ala.associates/wp-content/uploads/2016/09/b-card_v2-1080x675.png)
Vygon launches new product
![Novasep appoints Dr. François D’Hooge as bioconjugation unit manager](https://ala.associates/wp-content/uploads/2016/11/D_HOOGE-Francois-1080x675.jpg)
Novasep appoints Dr. François D’Hooge as bioconjugation unit manager
![ULIS launches Micro80 Gen2TM thermal sensor aimed at large-volume applications](https://ala.associates/wp-content/uploads/2016/09/ULIS_Micro80-Gen2-3-1080x675.jpg)
ULIS launches Micro80 Gen2TM thermal sensor aimed at large-volume applications
![CiToxLAB appoints Alan Bartlett as Senior Director, Global Laboratory Operations](https://ala.associates/wp-content/uploads/2016/09/Lab_picture-1080x675.jpg)
CiToxLAB appoints Alan Bartlett as Senior Director, Global Laboratory Operations
![GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer](https://ala.associates/wp-content/uploads/2016/08/Sdegove-JFProst-2-1080x675.jpg)
GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer
![Second Sight : résultats positifs à cinq ans de son système de prothèse épiretinienne Argus II](https://ala.associates/wp-content/uploads/2016/07/Glasses-VPU-LR.png)
Second Sight : résultats positifs à cinq ans de son système de prothèse épiretinienne Argus II
![Alizé Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences](https://ala.associates/wp-content/uploads/2016/08/DSC00880-1080x675.jpg)
Alizé Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences
![Biomunex presents novel data confirming optimal drug-like properties and activity of BiXAb® antibodies](https://ala.associates/wp-content/uploads/2016/07/Pierre-Emmanuel-Gerard-1080x675.jpg)
Biomunex presents novel data confirming optimal drug-like properties and activity of BiXAb® antibodies
![Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102](https://ala.associates/wp-content/uploads/2016/07/Marc-Martinell-1080x675.jpg)